Access the full text.
Sign up today, get DeepDyve free for 14 days.
Sandra Jones (2007)
Implications of behavioral decision theory for health marketingMarketing Theory, 7
Paul Rubin (2004)
Pharmaceutical Marketing: Medical and Industry BiasesHealth Economics
Peter Swenson, S. Greer (2002)
Foul Weather Friends: Big Business and Health Care Reform in the 1990s in Historical PerspectiveJournal of Health Politics, Policy and Law, 27
J. Donohue, E. Berndt, M. Rosenthal, A. Epstein, R. Frank (2004)
Effects of Pharmaceutical Promotion on Adherence to the Treatment Guidelines for DepressionMedical Care, 42
Long Term Care Statistics Branch Center for Disease Control and Prevention
National nursing home survey
J. Rizzo (1999)
Advertising and Competition in the Ethical Pharmaceutical Industry: The Case of Antihypertensive Drugs*The Journal of Law and Economics, 42
D. Dranove (2000)
The Economic Evolution of American Health Care: From Marcus Welby to Managed Care
K. Brekke, M. Kuhn
Direct to consumer advertising in pharmaceutical markets
L. Spiller, Walter Wymer (2001)
Physicians' Perceptions and Uses of Commercial Drug Information SourcesHealth Marketing Quarterly, 19
J. Harris, D. Grauman, R. Hemnani
Solving the accountable care conundrum
K. Bennett, M. Powell, J. Probst (2010)
Relative Financial Burden of Health Care ExpendituresSocial Work in Public Health, 25
L. Bates, R. Santerre (2007)
Do health insurers possess monopsony power in the hospital services industry?International Journal of Health Care Finance and Economics, 8
S. Cutrona, S. Woolhandler, K. Lasser, D. Bor, D. McCormick, D. Himmelstein (2008)
Characteristics of recipients of free prescription drug samples: a nationally representative analysis.American journal of public health, 98 2
P. Conway (2010)
How the Recovery Act's Federal Coordinating Council paved the way for the Patient-Centered Outcomes Research Institute.Health affairs, 29 11
P. Kanavos, J. Font, A. Mcguire (2007)
Product differentiation, competition and regulation of new drugs: the case of statins in four European countriesManagerial and Decision Economics, 28
Micah Hartman, Anne Martin, Olivia Nuccio, Aaron Catlin (2010)
Health spending growth at a historic low in 2008.Health affairs, 29 1
Daniel Hartung, David Evans, D. Haxby, D. Kraemer, Gabriel Andeen, L. Fagnan (2010)
Effect of Drug Sample Removal on Prescribing in a Family Practice ClinicThe Annals of Family Medicine, 8
R. Färe, S. Grosskopf (1992)
Malmquist Productivity Indexes and Fisher Ideal IndexesThe Economic Journal, 102
M. Pauly (1986)
Taxation, health insurance, and market failure in the medical economy.Journal of economic literature, 24 2
D. Ackerly, Seth Glickman, Seth Glickman, K. Schulman (2012)
Economic Content in Medical Journal Advertisements for Medical Devices and Prescription DrugsPharmacoEconomics, 28
K. Hanada (1982)
The evaluation of educational and economic effects on life expectation by linear regression analysis.Health policy and education, 3 1
Chemical Industry News and Intelligence
Nonbranded drugs are expected to continue their strong growth. But could the dearth of their new branded rivals cause the sector to hit a wall?
G. David, S. Markowitz, Seth Richards-Shubik (2009)
The Effects of Pharmaceutical Marketing and Promotion on Adverse Drug Events and RegulationDiffusion of Innovation eJournal
D. Chernichovsky (2002)
Pluralism, public choice, and the state in the emerging paradigm in health systems.The Milbank quarterly, 80 1
G. Kalyanaram (2009)
The endogenous modeling of the effect of direct‐to‐consumer advertising in prescription drugsInternational Journal of Pharmaceutical and Healthcare Marketing, 3
M. Goldberg, B. Davenport, T. Morellito
The big squeeze
P. Kotler, N. Roberto, N. Lee
Social Marketing
M. Morrisey
Health Insurance
K. Kalirajan, S. Bhide (2006)
Bias free measurement of technical efficiencyJournal of Applied Statistics, 33
S. Chimonas, T. Brennan, D. Rothman (2007)
Physicians and Drug Representatives: Exploring the Dynamics of the RelationshipJournal of General Internal Medicine, 22
Melissa Fischer, M. Keough, Joann Baril, L. Saccoccio, K. Mazor, Elissa Ladd, A. Worley, J. Gurwitz (2009)
Prescribers and Pharmaceutical Representatives: Why Are We Still Meeting?Journal of General Internal Medicine, 24
S. McGuire
Expect big pharma layoffs of 2007 to continue: report
Investment Weekly News
ZRG partners life science hiring index edges up globally in Q 3, but mixed signals appear
F. Scherer, D. Ross
Industrial Market Structure and Economic Market Performance
US Bureau of the Census
Statistical Abstract of the United States: 2011
G. Mooney (2002)
The Danish health care system: it ain't broke... so don't fix it.Health policy, 59 2
M. Rosenthal, E. Berndt, J. Donohue, R. Frank, A. Epstein (2002)
Promotion of prescription drugs to consumers.The New England journal of medicine, 346 7
B. Mintjes, M. Barer, R. Kravitz, K. Bassett, J. Lexchin, A. Kazanjian, R.G. Evans, R. Pan, S.A. Marion
How does direct‐to‐consumer advertising (DCTA) affect prescribing?
The Economist
Pass the pills
Health Systems Trust
Health statistics
D. Haxby
Pharmaceutical industry marketing and influence
World Bank
World Development Report: Development and Climate Change
S. Greenhouse (2008)
The Big Squeeze: Tough Times for the American Worker
C. Schoen, R. Osborn, S. How, M. Doty, J. Peugh (2008)
In chronic condition: experiences of patients with complex health care needs, in eight countries, 2008.Health affairs, 28 1
E. Berndt (2002)
Pharmaceuticals in U.S. health care: determinants of quantity and price.The journal of economic perspectives : a journal of the American Economic Association, 16 4
F. Lichtenberg (2010)
Pharmaceutical Price Discrimination and Social WelfareCapitalism and Society, 5
Charles Pettijohn, E. Rozell, Andrew Newman (2010)
The relationship between emotional intelligence and customer orientation for pharmaceutical salespeopleInternational Journal of Pharmaceutical and Healthcare Marketing, 4
D. Gardner, B. Mintzes, A. Ostry (2003)
Direct-to-consumer prescription drug advertising in Canada: permission by default?CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 169 5
L. Rodgers (2008)
Is American Health Care Uniquely Inefficient
P. Neumann, C. Fang, Joshua Cohen (2012)
30 Years of Pharmaceutical Cost-Utility AnalysesPharmacoEconomics, 27
Fadi Alkhateeb, N. Khanfar, K. Clauson (2009)
Characteristics of Physicians Who Frequently See Pharmaceutical Sales RepresentativesJournal of Hospital Marketing & Public Relations, 19
B. Luce (2005)
What will it take to make cost-effectiveness analysis acceptable in the United States?Medical care, 43 7 Suppl
Bureau of Labor Statistics
Employment by industry, occupation, and percent distribution, 2008 and projected 2018
M. Holler, Martin Leroch (2010)
Efficiency and justice revisitedEuropean Journal of Political Economy, 26
E. Chamberlain
Theory of Monopolistic Competition
D. Delorme, J. Huh, Leonard Reid, S. An (2010)
The state of public research on over-the-counter drug advertisingInternational Journal of Pharmaceutical and Healthcare Marketing, 4
J. Pereira (1990)
The economics of inequality in health: a bibliography.Social science & medicine, 31 3
L. Spiller, W. Wymer
Physicians' perceptions and uses of commercial drug information sources: an examination of pharmaceutical marketing to physicians
John Harris, D. Grauman, Rashi Hemnani (2010)
Solving the ACO conundrum.Healthcare financial management : journal of the Healthcare Financial Management Association, 64 11
Ray Robinson (1999)
Limits to rationality: economics, economists and priority setting.Health policy, 49 1-2
G. Alexander, James Zhang, James Zhang, Anirban Basu (2007)
1 CHARACTERISTICS OF PATIENTS RECEIVING PHARMACEUTICAL SAMPLES AND ASSOCIATION BETWEEN SAMPLE RECEIPT AND OUT-OF-POCKET PRESCRIPTION COSTS.Journal of Investigative Medicine, 55
CMS
Updated national health expenditure projections 2009‐2019
J. Kingsdale, J. Bertko (2010)
Insurance exchanges under health reform: six design issues for the states.Health affairs, 29 6
P. Neumann, C. Fang, J. Cohen
30 years of pharmaceutical cost‐utility analyses: growth, diversity and methodological improvement
M. Montefiori (2008)
Information vs advertising in the market for hospital careInternational Journal of Health Care Finance and Economics, 8
J. Donohue, M. Cevasco, M. Rosenthal (2007)
A decade of direct-to-consumer advertising of prescription drugs.The New England journal of medicine, 357 7
Glenn Follette, Louise Sheiner (2005)
The Sustainability of Health Spending GrowthNational Tax Journal, 58
T. Huddle (2008)
Drug Reps and the Academic Medical Center: a case for management rather than prohibitionPerspectives in Biology and Medicine, 51
CMS
National health expenditure projections 2009‐2019
Fadi Alkhateeb, W. Doucette (2008)
Electronic detailing (e‐detailing) of pharmaceuticals to physicians: a reviewInternational Journal of Pharmaceutical and Healthcare Marketing, 2
D. Staiger, J. Spetz, C. Phibbs (1999)
Is There Monopsony in the Labor Market? Evidence from a Natural ExperimentJournal of Labor Economics, 28
F. Alkhateeb, N. Khanfar, K. Clauson
Characteristics of physicians who see pharmaceutical sales representatives
M. Gagnon, J. Lexchin (2008)
The Cost of Pushing Pills: A New Estimate of Pharmaceutical Promotion Expenditures in the United StatesPLoS Medicine, 5
Christopher Truffer, Sean Keehan, Sheila Smith, J. Cylus, Andrea Sisko, J. Poisal, Joseph Lizonitz, M. Clemens (2010)
Health spending projections through 2019: the recession's impact continues.Health affairs, 29 3
J. Newhouse (1977)
Medical-care expenditure: a cross-national survey.The Journal of human resources, 12 1
T. Klumpp, Xuejuan Su (2010)
Open Access and Dynamic EfficiencyAmerican Economic Journal: Microeconomics, 2
C. Torr (1985)
Notes and Comments: Involuntary Unemployment and EquilibriumSouth African Journal of Economics, 53
W. Zinn, J. Sheth, Dennis Garrett (1987)
Marketing Theory: Classic and Contemporary ReadingsJournal of Marketing, 51
Congressional Budget Office
The long‐term outlook for health care spending
IMS Health
Product sampling in a new era of cost efficiencies
John Westfall, Jennifer McCabe, Richard Nicholas (1997)
Personal use of drug samples by physicians and office staff.JAMA, 278 2
K. Winstein, S. Vranica
Drug firms spending on consumer ads fell 8% in '08, a rare marketing pullback
IMS Health
Total US promotional spend by type, 2009
Organization for Economic Co‐operation and Development
OECD health data‐selected data
James Robinson, P. Ginsburg (2009)
Consumer-driven health care: promise and performance.Health affairs, 28 2
T. Caudill, M. Johnson, Eugene Rich, McKinney Wp (1996)
Physicians, pharmaceutical sales representatives, and the cost of prescribing.Archives of family medicine, 5 4
Bureau of Labor Statistics
Consumer price index – all urban consumers – all items
T. Huddle
The pitfalls of deducing ethics from behavioral economics: why the association of American medical colleges in wrong about pharmaceutical detailing
T. Huddle (2010)
Response to Open Peer Commentaries on “The Pitfalls of Deducing Ethics from Economics: Why the Association of American Medical Colleges is Wrong About Pharmaceutical Detailing”The American Journal of Bioethics, 10
J. Leach (2009)
Income Disparity, Inequity Aversion and the Design of the Healthcare SystemSRPN: Social Economics (Topic)
J. Kett, P. Starr (1983)
The Social Transformation of American MedicineJournal of Interdisciplinary History, 14
C. Tisdell (1985)
Conceptual Issues in the Measurement of Economic and Productive EfficienciesSouth African Journal of Economics, 53
Purpose – The purpose of this paper is to consider the efficiency of US healthcare in an international context. The paper emphasizes the concept of efficiency and explores implications for pharmaceutical marketing. Design/methodology/approach – Literature review, economic theory, secondary data and bivariate regression were used to describe and evaluate US healthcare spending and pharmaceutical marketing. Findings – US healthcare spending is inordinately high as a share of gross domestic product within developed countries and this is associated with a relatively high share of private finance. But public sector finance is displacing private payment and this trend is especially pronounced for pharmaceuticals. Public finance combined with fiscal pressure can be expected to curb use of pharmaceutical detailing and other forms of marketing. The limits of affordability are not well assessed and socio‐economic institutions to facilitate decisions about present and future costs have yet to evolve. Originality/value – This paper provides a macro perspective for healthcare finance and the marketing of pharmaceuticals. It pioneers analysis of economics and international healthcare systems integrated with the foundations of demand for pharmaceutical marketing.
International Journal of Pharmaceutical and Healthcare Marketing – Emerald Publishing
Published: Jun 28, 2011
Keywords: National health expenditures; Efficiency; Pharmaceuticals industry; Marketing; Advertising; United States of America
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.